Cervical Cancer

Detailed Overview

Squamous cell carcinoma accounts for roughly 80% of cases, while adenocarcinoma makes up most of the remainder. Early-stage cervical cancer is typically asymptomatic, underscoring the vital role of routine Pap smears and primary HPV testing. When symptoms do occur, abnormal vaginal bleeding—particularly postcoital bleeding—is the classic presentation. Treatment ranges from fertility-sparing excisional procedures for early disease to radical hysterectomy or concurrent chemoradiation for more advanced stages. Unlike many other cancers, cervical cancer staging is heavily clinical, incorporating physical examination and basic imaging.

Epidemiology & Demographics

Worldwide, it is the 4th most common cancer in women. Incidence is drastically lower in countries with established screening programs. In the US, there are about 14,000 new cases annually. It primarily affects women between ages 35 and 44.

Etiological Mechanism

Persistent, chronic infection with high-risk strains of Human Papillomavirus (HPV). HPV types 16 and 18 are responsible for approximately 70% of all cervical cancers.

Primary Causes

HPV infection acquired through sexual contact. The virus infects the basal cells of the cervical transformation zone. In a minority of women, the immune system fails to clear the virus, leading to chronic infection and oncogenesis.

• HPV Infection: The necessary, albeit not always sufficient, cause of cervical cancer.
• Lack of Screening: Failure to undergo regular Pap smears is the largest risk factor in developed nations.
• Immunosuppression: HIV infection or chronic immunosuppressive therapy severely impairs the body's ability to clear HPV.
• Smoking: Increases the risk of squamous cell carcinoma by acting as a co-factor in oncogenesis.
• Early/Multiple Sexual Partners: Increases the statistical likelihood of acquiring high-risk HPV strains.

High-risk HPV integrates its circular double-stranded DNA into the host cell genome. This integration disrupts the viral E2 gene, leading to uninhibited expression of viral oncoproteins E6 and E7. E6 binds to and degrades the host TP53 tumor suppressor protein, preventing apoptosis. E7 binds to and inactivates the host Retinoblastoma (Rb) protein, pushing the cell inappropriately into the S-phase of the cell cycle. The resulting uncontrolled cellular proliferation leads to dysplasia (CIN 1 to CIN 3) and eventually breaches the basement membrane to become invasive carcinoma, spreading locally to the vagina, parametrium, and pelvic sidewall, and metastasizing via lymphatics.

Characteristic Clinical Presentation

• Abnormal Vaginal Bleeding: Includes postcoital bleeding (classic), intermenstrual bleeding, or heavy/prolonged periods.
• Vaginal Discharge: Foul-smelling, watery, or blood-tinged discharge due to tumor necrosis.
• Pelvic Pain: Dull ache radiating to the back or legs, suggesting invasion of pelvic nerves.
• Asymptomatic: The norm for early-stage disease and precancerous lesions.

Physical Examination Signs

• Visible exophytic, friable, or ulcerated mass on the cervix upon speculum exam
• Hard, nodular parametria on bimanual pelvic examination
• Lower extremity edema (if pelvic nodes compress iliac veins)

• Obstructive Uropathy: Bilateral ureteral obstruction by tumor can cause renal failure, historically a leading cause of death.
• Vesicovaginal or Rectovaginal Fistula: Abnormal connections between organs due to tumor invasion or severe radiation damage.
• Radiation Toxicity: Radiation proctitis, cystitis, and premature menopause.
• Severe Hemorrhage: Erosion of the tumor into major pelvic vessels.

Diagnostic Criteria & Guidelines

Diagnosis is confirmed via a tissue biopsy. Abnormal screening (Pap/HPV) leads to colposcopy, where acetic acid is applied to highlight acetowhite changes, allowing for targeted punch biopsies. If invasive cancer is suspected, a larger biopsy or LEEP is performed.

Differential Diagnosis

• Cervical Polyps
• Cervicitis (e.g., Chlamydia, Gonorrhea)
• Endometrial Cancer
• Vaginal Cancer

Laboratory Tests & Biomarkers

• Pap Smear Cytology: Shows abnormal squamous cells (e.g., ASC-US, LSIL, HSIL).
• Primary HPV DNA Test: Positive for high-risk HPV types (e.g., 16, 18, 31, 33).
• Creatinine: Elevated if there is ureteral obstruction causing renal failure.

Imaging Modalities & Findings

• Pelvic MRI:
• PET/CT Scan:

• Stage I
  Carcinoma strictly confined to the cervix.
• Stage II
  Tumor invades beyond the uterus but has not reached the pelvic wall or lower third of the vagina.
• Stage III
  Tumor extends to the pelvic wall, involves the lower third of the vagina, or causes hydronephrosis.
• Stage IV
  Tumor invades the mucosa of the bladder or rectum, or distant metastasis is present.

Second-Line & Adjunctive Therapy

For recurrent or metastatic disease (Stage IVB): Systemic palliative chemotherapy. Standard regimen is Cisplatin/Paclitaxel combined with Bevacizumab (an anti-VEGF targeted antibody). Pembrolizumab (immunotherapy) is added if the tumor expresses PD-L1.

Surgical & Procedural Management

Radical Hysterectomy involves removing the uterus, cervix, upper vagina, and parametrial tissues. Pelvic exenteration is a massive salvage surgery reserved for central pelvic recurrence after radiation, involving removal of the bladder, rectum, and reproductive organs.

Recommended Lifestyle Changes

• Smoking cessation is critical as it aids in clearing HPV infections and reduces recurrence risk.
• Use of barrier contraception (condoms) to reduce transmission of other STIs and HPV types.
• Routine follow-up is imperative even after curative therapy.

Patient Counseling & Advice

Educate the patient that treatment (surgery or radiation) will result in infertility and may cause sexual dysfunction (vaginal stenosis, dryness). Provide psychological support due to the profound impact on body image and reproductive capabilities.

Follow-Up & Monitoring Schedule

History, physical exam, and vault cytology (Pap smear of the surgical stump) every 3-6 months for 2 years, then every 6-12 months for 3 years, then annually. Monitor closely for leg swelling or localized pain indicating recurrence.

Preventive Strategies

HPV Vaccination: The 9-valent HPV vaccine (Gardasil 9) given to boys and girls starting at age 11-12 prevents infection from the strains causing 90% of cancers. Secondary prevention via screening: Pap smear alone every 3 years (ages 21-29), then HPV co-testing every 5 years (ages 30-65).

Highly stage-dependent. 5-year survival for localized early stage is >90%. For regional disease treated with chemoradiation, it is ~60%. For metastatic disease, it drops to ~17%.